Efficacy Study of Trichuris Suis Ova to Treat Chronic Plaque Psoriasis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01948271|
Recruitment Status : Terminated (lack of efficacy)
First Posted : September 23, 2013
Last Update Posted : September 15, 2016
|Condition or disease||Intervention/treatment||Phase|
|Psoriasis||Drug: Trichuris Suis Ova||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||3 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open-label Pilot Study to Assess the Safety and Efficacy of Trichuris Suis Ova for the Treatment of Moderate to Severe Chronic Plaque Psoriasis|
|Study Start Date :||July 2013|
|Primary Completion Date :||September 2014|
|Study Completion Date :||September 2014|
Experimental: TSO 7500
Subjects in this arm will receive doses of 7500 trichuris suis ova every two weeks, starting at the baseline visit, for a total of 8 doses.
Drug: Trichuris Suis Ova
During the treatment phase, study drug will be provided in a liquid form and will be administered every 2 weeks, starting with the Baseline visit, through Week 14.
Other Name: TSO 7500
- Physician's area and severity index (PASI) [ Time Frame: Screening, baseline, weeks 2, 4, 6, 8, 10, 12, 14, and 16 ]The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. PASI produces a numeric score that can range from 0 to 72 based on the body surface area of involvement and the severity of disease (induration, erythema and scale). A PASI-50 response is defined as ≥50% improvement in PASI score from baseline; PASI-75 and PASI-90 are similarly defined.
- Safety and tolerability [ Time Frame: Screening, baseline, weeks 2, 4, 6, 8, 10, 12, 14, 16, 20, and 38 ]Evaluated via the frequency and severity of adverse events, changes in physical examinations, stool studies (ova and parasites, culture, clostridium difficile toxin, and blood), clinical laboratories (liver function tests, creatine phosphokinase, complete metabolic profile, complete blood count), and vital signs (blood pressure, pulse and temperature).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01948271
|United States, Massachusetts|
|Tufts Medical Center|
|Boston, Massachusetts, United States, 02111|
|Principal Investigator:||Alice B Gottlieb, MD, PhD||Tufts Medical Center, Department of Dermatology|